Past Press Releases - Cytheris SA

October 24, 2012
Cytheris announces US Orphan Drug Designation for CYT107 for the treatment of PML
Cytheris announces US Orphan Drug Designation for CYT107 for the treatment of Progressive Multifocal Leucoencephalopathy (PML). More

July 10, 2012
Cytheris announces CYT107 orphan drug designation in Europe for the treatment of PML
Cytheris announces CYT107 orphan drug designation in Europe for the treatment of Progressive Multifocal Leucoencephalopathy (PML). More

February 22, 2011
Cytheris announces publication of preclinical study in Cell ...
Cytheris announces publication of preclinical study in Cell showing that interleukin-7 engages multiple mechanisms to overcome chronic viral infection and limit organ pathology. More

December 7, 2010
Cytheris announces interim results of Phase I study showing that recombinant human interleukin-7 ...
Cytheris announces interim results of Phase I study showing that recombinant human interleukin-7 (CYT107) promotes T-cell recovery following T-cell depleted allogeneic hematopoietic stem cell transplantation. More

October 19, 2010
Cytheris announces initiation of ORVACS-sponsored phase II clinical study
Cytheris announces initiation of ORVACS-sponsored phase II clinical study combining immunomodulatory intervention with Interleukin-7 (CYT107) and antiretroviral intensification with raltegravir and maraviroc to attack the viral reservoir of HIV patients More

March 16, 2010
Cytheris announces publication of preclinical study in Journal of Immunology ...
Cytheris announces publication of preclinical study in Journal of Immunology showing Interleukin-7 promotes T cell viability, trafficking and functionality while improving survival in sepsis. More

February 2, 2010
Cytheris announces notice of allowance for U.S. patent covering the preparation and uses of CYT107
Cytheris announces notice of allowance for U.S. patent covering the preparation and uses of its glycosylated recombinant human interleukin-7 (CYT107) More

December 8, 2009
Cytheris announces initiation of CONVERT, a Phase I/IIa study ...
Cytheris announces initiation of CONVERT, a Phase I/IIa study of recombinant human Interleukin-7 (CYT107) in combination with antiviral therapy and vaccination for treatment of chronic hepatitis B virus. More

November 23, 2009
Cytheris announces initiation of NCI/NIH-sponsored phase I/IIa clinical study
Cytheris announces initiation of NCI/NIH-sponsored phase I/IIa clinical study of tumor vaccination and interleukin-7 (IL-7) in patients with high risk pediatric solid tumors. More

October 14, 2009
Cytheris announces initiation of NIAID/NIH-sponsored Phase I/IIa clinical trial of interleukin-7
Study to focus on immunotherapy for treatment of idiopathic CD4 lymphocytopenia (ICL), a rare condition for which no treatment currently exists More

October 28, 2008
Cytheris initiates Asian Phase I/IIa clinical trial of Interleukin-7 (IL-7) as an immunotherapy ...
Taiwan trial studies patients who failed to achieve SVR with standard treatment, and complements Company's two other investigations in naïve and previously non-responsive HCV patients currently ongoing in Europe More

July 15, 2008
Cytheris receives EUR 1.5 million (USD 2.3 million) from OSEO for HCV clinical development program
Highly competitive government award for Paris region recognizes potential of Interleukin-7 as an immunotherapy More

June 26, 2008
Cytheris announces publication of IL-7 oncology data in The Journal of Experimental Medicine
Results of a second phase 1 trial in oncology further demonstrate the potential of Interleukin-7 to induce dramatic and prolonged CD4 and CD8 T cell expansion More

April 23, 2008
Cytheris announces new phase I study of Interleukin-7 as immunotherapy
Cytheris announces new phase I study of Interleukin-7 as immunotherapy in treatment of bone barrow or peripheral blood stem cell transplant patients More

November 26, 2007
Cytheris appoints Richard Keatinge as Chief Business Officer
Company further strengthens management team with experienced international biotech business executive More

September 26, 2007
Cytheris expands Interleukin-7 clinical development program with phase I/IIa trial in HIV
Cytheris, a clinical stage biopharmaceutical company focused on research and development of new therapies for immune modulation, today announced expansion of the clinical trial program for CYT107, the company's recombinant human Interleukin-7 (IL-7), with the initiation of a Phase I/IIa clinical trial in HIV patients. More